Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of JRF103 in advanced solid tumors
CTR20241885Phase 2Active
- Sponsor
- Chengdu Jinruijiye Biotechnology
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JRF103 in Nonhematologic neoplasms, sponsored by Chengdu Jinruijiye Biotechnology. Started May 2024; status: active.
02
Drugs
JRF103
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20241885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241885.